Drug Approval | September 21, 2021
U.S. FDA approves Samsung Bioepis and Biogen’s BYOOVIZ biosimilar
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
The recipient is a 57-year-old woman who was suffering from severe biventricular heart failure and had undergone cardiac surgery several years ago
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
The deal is expected to close in the fourth quarter of 2021 and will enable Roche to further expand the portfolio. TIB Molbiol excels in ultra-rapid assay development of emerging infectious diseases
The pharma park will be built at an estimated cost of Rs 34.94 crore and will be spread over 50 acres at Chanho close to Ranchi
Research collaboration covers multiple antibody research programs
Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
The medicine is now approved for eight indications across five different types of cancer in China.
The lab will offer over 4,000 clinical tests and profiles and can conduct over 20,000 sample tests per month.
Subscribe To Our Newsletter & Stay Updated
